Genmab — August 2017
-
jamen så tager vi den igen, nu da MW er på banen http://medwatch.dk/Medicinal___Biotek/article9826468.ece
-
Takeda buys into Astrazeneca's early stage Parkinson's program - http://www.bioworld.com/content/takeda-buys-astrazenecas-early-stage-parkinsons-program
-
Det er sgu en sund premium, som Gilead betaler for Kite... (jvf artiklen)
-
must be
related to this, Novartis only up small though https://globenewswire.com/news-release/2017/08/30/1104337/0/en/Novartis-receives-first-ever-FDA-approval-for-a-CAR-T-cell-therapy-Kymriah-TM-CTL019-for-children-and-young-adults-with-B-cell-ALL-that-is-refractory-or-has-relapsed-at-least-twice.html http://www.businessinsider.com/fda-approves-novartis-car-t-cancer-treatment-2017-8?international=true&r=US&IR=T -
-
For retfærdigehedens skal vel nævnes at de $ 700.000 er en gang, $ 90.000 er per år.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind